McNicoll Lewis & Vlak Starts Sunesis Pharmaceuticals (SNSS) at Buy; Vosaroxin in Pivotal Phase III AML Trial
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Price: $5.32 --0%
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 7
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 7
Join SI Premium – FREE
McNicoll Lewis & Vlak initiates coverage on Sunesis Pharmaceuticals (NASDAQ: SNSS) with a Buy. PT $3.50.
MLV analyst said, "The company’s lead drug candidate, vosaroxin, is a quinolone derivative currently being evaluated in a pivotal Phase III trial called VALOR for the treatment of relapsed and refractory acute myeloid leukemia (AML)...We believe the interim data review of VALOR has the potential of being a catalyst for Sunesis’ stock. The trial could be stopped early due to efficacy, the best possible outcome, or due to futility, the worst possible outcome. More likely, we believe the trial will continue as planned with possible product launch in 2014."
"Although vosaroxin is Sunesis’ only significant asset at this time, we think Phase I/II trial results suggest it is an active drug and that the adaptive design of VALOR increases the probability of a successful trial."
For more ratings news on Sunesis Pharmaceuticals click here and for the rating history of Sunesis Pharmaceuticals click here.
Shares of Sunesis Pharmaceuticals closed at $1.22 yesterday.
MLV analyst said, "The company’s lead drug candidate, vosaroxin, is a quinolone derivative currently being evaluated in a pivotal Phase III trial called VALOR for the treatment of relapsed and refractory acute myeloid leukemia (AML)...We believe the interim data review of VALOR has the potential of being a catalyst for Sunesis’ stock. The trial could be stopped early due to efficacy, the best possible outcome, or due to futility, the worst possible outcome. More likely, we believe the trial will continue as planned with possible product launch in 2014."
"Although vosaroxin is Sunesis’ only significant asset at this time, we think Phase I/II trial results suggest it is an active drug and that the adaptive design of VALOR increases the probability of a successful trial."
For more ratings news on Sunesis Pharmaceuticals click here and for the rating history of Sunesis Pharmaceuticals click here.
Shares of Sunesis Pharmaceuticals closed at $1.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Starts Bitfarms Ltd. (BITF) at Outperform
- Craig-Hallum Assumes Guardant Health (GH) at Buy, 'We think that GH is undervalued'
- Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
